EGFR- and Integrin α_Vβ₃-Targeting Peptides as Potential Radiometal-Labeled Radiopharmaceuticals for Cancer...

Area of Science:

• Oncology
• Molecular Imaging
• Drug Development

Background:

• Cancer theranostics utilizes targeted molecular agents, with peptides emerging as alternatives to antibodies.
• Peptides target specific receptors like Epidermal Growth Factor receptor (EGFR) and integrin αVβ3, crucial for tumor progression.
• Antibody-based therapies show promise, but peptides offer benefits like smaller size and enhanced bioavailability.

Purpose of the Study:

• To provide a comprehensive review of EGFR- and integrin αVβ3-targeting peptides in cancer theranostics.
• To synthesize current research on peptide synthesis, radiolabeling, and evaluation.
• To identify research gaps and inform future directions in peptide-based cancer theranostics.

Main Methods:

• Literature review of scientific publications on peptide-based cancer theranostics.
• Analysis of synthesis and radiolabeling techniques for targeted peptides.
• Evaluation of preclinical and clinical data for EGFR- and integrin αVβ3-targeting peptides.

Main Results:

• Peptides offer advantages in tumor penetration and reduced toxicity compared to antibodies.
• Challenges include lower binding affinity and rapid blood clearance, impacting efficacy and diagnostics.
• Advancements in peptide design and targeting strategies are continuously being made.

Conclusions:

• EGFR- and integrin αVβ3-targeting peptides hold significant potential in cancer theranostics.
• Addressing limitations in binding affinity and pharmacokinetics is crucial for clinical translation.
• Further research is needed to optimize peptide agents for enhanced diagnostic precision and therapeutic outcomes.